New mRNA flu vaccine shows promise in early trial
NCT ID NCT06179446
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new mRNA vaccine designed to protect against a future flu pandemic. Healthy adults aged 18-49 and 65-84 received either the experimental vaccine, a licensed flu shot, or a placebo. Researchers monitored safety and immune responses for about 13 months to see if the vaccine is well-tolerated and triggers protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRIPPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
-
Research Centers of America
Hollywood, Florida, 33024, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts